ProQR Therapeutics (PRQR) Invested Capital (2021 - 2025)

ProQR Therapeutics' Invested Capital history spans 4 years, with the latest figure at $99.5 million for Q4 2024.

  • For Q4 2024, Invested Capital rose 102.5% year-over-year to $99.5 million; the TTM value through Dec 2024 reached $99.5 million, up 102.5%, while the annual FY2024 figure was $100.8 million, 104.01% up from the prior year.
  • Invested Capital for Q4 2024 was $99.5 million at ProQR Therapeutics, up from $49.2 million in the prior quarter.
  • Across five years, Invested Capital topped out at $149.2 million in Q4 2021 and bottomed at $49.2 million in Q4 2023.
  • The 4-year median for Invested Capital is $86.3 million (2022), against an average of $92.7 million.
  • The largest annual shift saw Invested Capital tumbled 51.01% in 2022 before it soared 102.5% in 2024.
  • A 4-year view of Invested Capital shows it stood at $149.2 million in 2021, then tumbled by 51.01% to $73.1 million in 2022, then plummeted by 32.74% to $49.2 million in 2023, then skyrocketed by 102.5% to $99.5 million in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Invested Capital are $99.5 million (Q4 2024), $49.2 million (Q4 2023), and $73.1 million (Q4 2022).